{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T22:36:56Z","timestamp":1761172616020,"version":"build-2065373602"},"reference-count":21,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81703618"],"award-info":[{"award-number":["81703618"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal de Mycologie M\u00e9dicale"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1016\/j.mycmed.2018.03.005","type":"journal-article","created":{"date-parts":[[2018,6,14]],"date-time":"2018-06-14T20:34:01Z","timestamp":1529008441000},"page":"310-313","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["In vitro susceptibility of Candida spp. to fluconazole, itraconazole and voriconazole and the correlation between triazoles susceptibility: Results from a five-year study"],"prefix":"10.1016","volume":"28","author":[{"given":"J.","family":"Lei","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.mycmed.2018.03.005_bib0110","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1128\/CMR.00029-06","article-title":"Epidemiology of invasive candidiasis: a persistent public health problem","volume":"20","author":"Pfaller","year":"2007","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.mycmed.2018.03.005_bib0115","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/cid\/civ933","article-title":"Clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America","volume":"62","author":"Pappas","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.mycmed.2018.03.005_bib0120","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3201\/eid2301.161198","article-title":"Epidemiology of hospitalizations associated with invasive candidiasis, United States, 2002\u20132012","volume":"23","author":"Strollo","year":"2016","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.mycmed.2018.03.005_bib0125","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1111\/tid.12613","article-title":"The epidemiology and outcomes of invasive Candida infections among organ transplant recipients in the United States: results of the Transplant-Associated Infection Surveillance Network (TRANSNET)","volume":"18","author":"Andes","year":"2016","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.mycmed.2018.03.005_bib0130","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1111\/myc.12553","article-title":"Antifungal susceptibility of Candida species isolated from patients with candidemia in southern Taiwan, 2007-2012: impact of new antifungal breakpoints","volume":"60","author":"Chen","year":"2017","journal-title":"Mycoses"},{"key":"10.1016\/j.mycmed.2018.03.005_bib0135","doi-asserted-by":"crossref","first-page":"122","DOI":"10.5578\/mb.10682","article-title":"Antifungal susceptibility profiles of Candida species to triazole: application of new CLSI species-specific clinical breakpoints and epidemiological cutoff values for characterization of antifungal resistance","volume":"50","author":"Karabicak","year":"2016","journal-title":"Mikrobiyol Bul"},{"key":"10.1016\/j.mycmed.2018.03.005_bib0140","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1093\/jac\/dku460","article-title":"Antifungal susceptibilities of Candida glabrata species complex, Candida krusei, Candida parapsilosis species complex and Candida tropicalis causing invasive candidiasis in China: 3-year national surveillance","volume":"70","author":"Xiao","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.mycmed.2018.03.005_bib0145","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.2165\/11596540-000000000-00000","article-title":"Triazole antifungal agents in invasive fungal infections: a comparative review","volume":"71","author":"Lass-Florl","year":"2011","journal-title":"Drugs"},{"key":"10.1016\/j.mycmed.2018.03.005_bib0150","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1086\/588660","volume":"46","author":"De Pauw","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.mycmed.2018.03.005_bib0155","doi-asserted-by":"crossref","first-page":"e114004","DOI":"10.1371\/journal.pone.0114004","article-title":"The widely used ATB FUNGUS 3 automated readings in China and its misleading high MICs of Candida spp. to azoles: challenges for developing countries\u2019 clinical microbiology labs","volume":"9","author":"Zhang","year":"2014","journal-title":"Plos One"},{"key":"10.1016\/j.mycmed.2018.03.005_bib0160","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.ijantimicag.2008.05.023","article-title":"Activity of voriconazole, itraconazole, fluconazole and amphotericin B in vitro against 1763 yeasts from 472 patients in the voriconazole phase III clinical studies","volume":"32","author":"Johnson","year":"2008","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.mycmed.2018.03.005_bib0165","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1111\/myc.12299","article-title":"In vitro antifungal susceptibilities of isolates of Candida spp. and Aspergillus spp. from China to nine systemically active antifungal agents: data from the SENTRY antifungal surveillance program, 2010 through 2012","volume":"58","author":"Pfaller","year":"2015","journal-title":"Mycoses"},{"key":"10.1016\/j.mycmed.2018.03.005_bib0170","doi-asserted-by":"crossref","first-page":"2691","DOI":"10.1128\/JCM.01230-13","article-title":"Epidemiological cutoff values for fluconazole, itraconazole, posaconazole, and voriconazole for six Candida species as determined by the colorimetric Sensititre YeastOne method","volume":"51","author":"Canton","year":"2013","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.mycmed.2018.03.005_bib0175","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1128\/JCM.02117-09","article-title":"Results from the ARTEMIS DISK Global Antifungal Surveillance Study, 1997 to 2007: a 10.5-year analysis of susceptibilities of Candida Species to fluconazole and voriconazole as determined by CLSI standardized disk diffusion","volume":"48","author":"Pfaller","year":"2010","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.mycmed.2018.03.005_bib0180","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1128\/JCM.44.5.1740-1743.2006","article-title":"Clinical significance of azole antifungal drug cross-resistance in Candida glabrata","volume":"44","author":"Panackal","year":"2006","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.mycmed.2018.03.005_bib0185","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1128\/JCM.01551-06","article-title":"Use of fluconazole as a surrogate marker to predict susceptibility and resistance to voriconazole among 13,338 clinical isolates of Candida spp. Tested by clinical and laboratory standards institute-recommended broth microdilution methods","volume":"45","author":"Pfaller","year":"2007","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.mycmed.2018.03.005_bib0190","doi-asserted-by":"crossref","first-page":"649","DOI":"10.2165\/00003088-200645070-00002","article-title":"Pharmacokinetic\/pharmacodynamic profile of voriconazole","volume":"45","author":"Theuretzbacher","year":"2006","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.mycmed.2018.03.005_bib0195","doi-asserted-by":"crossref","first-page":"3244","DOI":"10.1093\/jac\/dku316","article-title":"Aspergillus fumigatus harbouring the sole Y121F mutation shows decreased susceptibility to voriconazole but maintained susceptibility to itraconazole and posaconazole","volume":"69","author":"Lescar","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.mycmed.2018.03.005_bib0200","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S1130-1406(08)70002-0","article-title":"Comparative evaluation of ATB Fungus 2 and Sensititre YeastOne panels for testing in vitro Candida antifungal susceptibility","volume":"25","author":"Eraso","year":"2008","journal-title":"Rev Iberoam Micol"},{"key":"10.1016\/j.mycmed.2018.03.005_bib0205","first-page":"7","article-title":"Comparison of the ATB\u00ae Fungus 2 with the AFST-EUCAST for in vitro susceptibility testing of Candida spp","volume":"46","author":"Ramos","year":"2014","journal-title":"Rev Univ Ind Santand Salud"},{"key":"10.1016\/j.mycmed.2018.03.005_bib0210","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1093\/jac\/dkm247","article-title":"In vitro susceptibilities to yeasts using the ATB FUNGUS 2 method, compared with Sensititre Yeast One and standard CLSI (NCCLS) M27-A2 methods","volume":"60","author":"Torres-Rodriguez","year":"2007","journal-title":"J Antimicrob Chemother"}],"container-title":["Journal de Mycologie M\u00e9dicale"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1156523317303645?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1156523317303645?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T05:20:11Z","timestamp":1761110411000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1156523317303645"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6]]},"references-count":21,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,6]]}},"alternative-id":["S1156523317303645"],"URL":"https:\/\/doi.org\/10.1016\/j.mycmed.2018.03.005","relation":{},"ISSN":["1156-5233"],"issn-type":[{"type":"print","value":"1156-5233"}],"subject":[],"published":{"date-parts":[[2018,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"In vitro susceptibility of Candida spp. to fluconazole, itraconazole and voriconazole and the correlation between triazoles susceptibility: Results from a five-year study","name":"articletitle","label":"Article Title"},{"value":"Journal de Mycologie M\u00e9dicale","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mycmed.2018.03.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}]}}